Jolanda Howe Sells 4,732 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 4,732 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $435,249.36. Following the sale, the senior vice president directly owned 8,429 shares of the company’s stock, valued at approximately $775,299.42. The trade was a 35.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Jolanda Howe also recently made the following trade(s):

• On Monday, February 2nd, Jolanda Howe sold 968 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $103.30, for a total value of $99,994.40.
• On Monday, January 26th, Jolanda Howe sold 842 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $96.19, for a total transaction of $80,991.98.
• On Thursday, January 22nd, Jolanda Howe sold 926 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total transaction of $86,423.58.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM traded up $3.91 on Tuesday, reaching $96.55. 865,362 shares of the company’s stock traded hands, compared to its average volume of 830,531. The stock has a 50-day simple moving average of $95.73 and a 200-day simple moving average of $80.84. Mirum Pharmaceuticals, Inc. has a 12 month low of $36.88 and a 12 month high of $109.28. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The business had revenue of $148.93 million during the quarter, compared to analysts’ expectations of $141.78 million. During the same period in the prior year, the firm posted $1.00 earnings per share. The firm’s revenue for the quarter was up 49.8% on a year-over-year basis. On average, research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on MIRM. Stifel Nicolaus upped their price target on shares of Mirum Pharmaceuticals from $98.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. TD Cowen upped their price objective on Mirum Pharmaceuticals from $115.00 to $117.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Leerink Partners decreased their price objective on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. Finally, Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $117.00.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Comerica Bank lifted its position in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares during the period. AQR Capital Management LLC grew its stake in shares of Mirum Pharmaceuticals by 307.3% during the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after purchasing an additional 37,028 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Mirum Pharmaceuticals by 7.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after buying an additional 1,720 shares in the last quarter. Caxton Associates LLP purchased a new position in shares of Mirum Pharmaceuticals in the 1st quarter valued at about $217,000. Finally, Empowered Funds LLC raised its stake in shares of Mirum Pharmaceuticals by 15.4% during the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after buying an additional 5,120 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.